SCHEMBL760785

SCHEMBL760785

O=S(=O)(Cl)c1cc(Cl)ccc1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 4/20 0.48
S100A4 P26447 2/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.44
TRPV4 Q9HBA0 1/20 0.43
FBP1 P09467 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 1/20 0.40
PTGS2 P35354 2/20 0.40
PTGS1 P23219 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL196679 0.84 TRPV4 (0.52) S100A4TRPV4KDM4EALDH1A1HPGD
SCHEMBL6562906 0.84 ACLY (0.47) ACLYS100A4PTGDR2FBP1KMT2A
Hydrochloric Acid SCHEMBL2766272 0.82 ACLY (0.46) ACLYS100A4PTGDR2FBP1KMT2A
SCHEMBL2894066 0.80 PTPRC (0.43) ACLYS100A4PTGDR2KMT2AKDM4E
SCHEMBL3873206 0.80 ACLY (0.39) ACLYPTGS2PTGS1ALDH1A1HSD17B10
SCHEMBL313390 0.78 ALDH1A1 (0.46) FBP1PTGS2PTGS1ALDH1A1HSD17B10
SCHEMBL9840644 0.77 KIF18A (0.51) ACLYKMT2AMEN1KDM4ECYP1A2
SCHEMBL4202592 0.77 PTGS2 (0.55) S100A4FBP1KDM4ECYP1A2PTGS2
SCHEMBL15879481 0.76 PTGS2 (0.48) KMT2AMEN1PTGS2PTGS1ALDH1A1
SCHEMBL6291041 0.76 PTPN1 (0.50) KMT2AMEN1KDM4ECYP1A2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841772-B1 TETRAHYDROFURANE DERIVATIVES FOR USE AS INHIBITORS OF MATRIX METALLOPROTEINASES SANOFI SA (FR) 2015-05-06 EP disclosed
EP-1670766-B1 Bicyclic imino acid derivatives for the treatment of (inter alia) diseases relating to the locomotor system SANOFI AVENTIS DEUTSCHLAND (DE) 2012-03-21 EP disclosed
US-8039481-B2 Tetrahydrofuran derivatives for use as inhibitors of matrix metalloproteinases SANOFI-AVENTIS (FR) 2011-10-18 US disclosed
US-20100279986-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2010-11-04 US disclosed
US-7803793-B2 Heterocyclic derived metalloprotease inhibitors JANSSEN PHARMACEUTICA NV (BE) 2010-09-28 US disclosed
US-20100105894-A1 Cyclopropane compounds and pharmaceutical use thereof JAPAN TOBACCO INC. 2010-04-29 US disclosed
EP-1694410-B1 CYCLOPROPANE DERIVATIVES AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2010-04-14 EP disclosed
EP-2089365-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2009-08-19 EP disclosed
US-20080306258-A1 Cyclopropane compounds and pharmaceutical use thereof JAPAN TOBACCO INC. 2008-12-11 US disclosed
US-20080261994-A1 CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. 2008-10-23 US disclosed
WO-2005030728-A1 BICYCLIC IMINO ACID DERIVATIVES USED AS INHIBITORS OF MATRIX-METALLOPROTEINASES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-04-07 WO disclosed
US-20030087945-A1 Sulfonylaminocarboxylic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-08 US disclosed
EP-0877018-B1 Sulfonylaminocarboxylic acids AVENTIS PHARMA GMBH (DE) 2003-05-02 EP disclosed
US-6451824-B1 Sulfonylaminocarboxylic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-09-17 US disclosed
US-6355673-B1 BONE DISORDERS; ANTIINFLAMMATORY AGENTS; WOUND HEALING AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-03-12 US disclosed
EP-0877019-B1 Substituted diaminocarboxylic acid HOECHST AG (DE) 2001-12-12 EP disclosed
US-6159995-A Substituted diaminocarboxylic acids AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-12 US disclosed
EP-0967201-A1 Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors Roche Diagnostics GmbH (DE) 1999-12-29 EP disclosed
EP-0877019-A1 Substituted diaminocarboxylic acid HOECHST AKTIENGESELLSCHAFT (DE) 1998-11-11 EP disclosed
EP-0877018-A1 Sulfonylaminocarboxylic acids HOECHST AKTIENGESELLSCHAFT (DE) 1998-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087945-A1 Sulfonylaminocarboxylic acids MMP1, SERPINB1, MMP3 ACLY 1461/4885S100A4 1080/4885PTGDR2 393/4885
US-20080261994-A1 CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MMP13, MMP9, MMP11 ACLY 672/4885S100A4 1351/4885PTGDR2 149/4885
US-20100279986-A1 HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS ADAM17, MMP25, ADAM33 ACLY 1564/4885S100A4 2556/4885PTGDR2 340/4885
US-20100105894-A1 Cyclopropane compounds and pharmaceutical use thereof MMP13, MMP9, MMP11 ACLY 672/4885S100A4 1351/4885PTGDR2 149/4885
US-20080306258-A1 Cyclopropane compounds and pharmaceutical use thereof MMP13, MMP9, MMP11 ACLY 673/4885S100A4 1351/4885PTGDR2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.